Escitalopram for agitation in Alzheimer's disease (S‐CitAD): Methods and design of an investigator‐initiated, randomized, controlled, multicenter clinical trial
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Introduction: Alzheimer's disease (AD) is a disabling, common cause of dementia, and agitation is one of the most common and distressing symptoms for patients with AD. Escitalopram for agitation in Alzheimer's disease (S‐CitAD) tests a novel, clinically derived therapeutic approach to treat agitation in patients with AD. Methods: S‐CitAD is a NIH‐funded, investigator‐initiated, randomized, multicenter clinical trial. Participants receive a structured psychosocial intervention (PSI) as standard of care. Participants without sufficient response to PSI are randomized to receive 15 mg escitalopram/day or a matching placebo in addition to PSI. Primary outcome is the Modified Alzheimer's Disease Cooperative Study ‐ Clinical Global Impression of Change (mADCS‐CGIC). Discussion: S‐CitAD will provide information about a practical, immediately available approach to treating agitation in patients with AD. S‐CitAD may become a model of how to evaluate and predict treatment response in patients with AD and agitation as a neuropsychiatric symptom (ClinicalTrials.gov Identifier: NCT03108846).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Bédard, M., Molloy, D. W., Squire, L., Dubois, S., Lever, J. A., & O'Donnell, M. (2001) · The Gerontologist · doi:10.1093/geront/41.5.652 · Cited by 1,691
Pharmacological Treatment of Neuropsychiatric Symptoms of Dementia: A Review of the Evidence
Sink, K. M., Holden, K. F., & Yaffe, K. (2005) · JAMA · doi:10.1001/jama.293.5.596 · Cited by 910
Point and 5‐year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study
Steinberg, M., Shao, H., Zandi, P., Lyketsos, C. G., Welsh‐Bohmer, K. A., Norton, M. C., Breitner, J. C. S., Steffens, D. C., & Tschanz, J. T. (2008) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1858 · Cited by 780 · cited 2×
“Almost all patients with AD experience NPS at some point [2].”
BackgroundSelf-citationEffect of Citalopram on Agitation in Alzheimer Disease: The CitAD Randomized Clinical Trial
Porsteinsson, A. P., Drye, L. T., Pollock, B. G., Devanand, D. P., Frangakis, C., Ismail, Z., Marano, C., Meinert, C. L., Mintzer, J. E., Munro, C. A., et al. (2014) · JAMA · doi:10.1001/jama.2014.93 · Cited by 572 · cited 4×
“CitAD [3] chose citalopram based on its neurochemical profile and success in treating agitation in patients with AD in two prior RCTs [34,35].”
BackgroundMethodInfluentialSelf-citationNeuropsychiatric symptoms in Alzheimer's disease: Past progress and anticipation of the future
Geda, Y. E., Schneider, L. S., Gitlin, L. N., Miller, D. S., Smith, G. S., Bell, J., Evans, J., Lee, M., Porsteinsson, A., Lanctôt, K. L., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.12.001 · Cited by 378 · cited 1×
“consortium [21] proposed that NPS result from damage to frontal-subcortical or cortico-cortical networks that mediate emotional processing, and/or from loss of regulation of these circuits by ascending monoaminergic systems, including the serotonin system.”
BackgroundSelf-citationPollock, B. G., Mulsant, B. H., Rosen, J., Sweet, R. A., Mazumdar, S., Bharucha, A., Marin, R., Jacob, N. J., Huber, K. A., Kastango, K. B., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.3.460 · Cited by 327
Self-citationPollock, B. G., Mulsant, B. H., Rosen, J., Mazumdar, S., Blakesley, R. E., Houck, P. R., & Huber, K. A. (2007) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3180cc1ff5 · Cited by 257 · cited 3×
“CitAD [3] chose citalopram based on its neurochemical profile and success in treating agitation in patients with AD in two prior RCTs [34,35].”
MethodSelf-citationGarcia-Alloza, M., Gil-Bea, F. J., Diez-Ariza, M., Chen, C. P. L.-H., Francis, P. T., Lasheras, B., & Ramirez, M. J. (2005) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2004.06.007 · Cited by 244 · cited 1×
“The role of the serotonin loss in the biology of agitation in patients with AD is supported by the following convergent findings: (1) in neuropathologic studies agitation is associated with loss of serotonergic innervation to the cortex [24,25], cholinergicserotonergic imbalance [26], and reduced serotonin 5HT1A recep…”
ResultNeuron loss in key cholinergic and aminergic nuclei in Alzheimer disease: a meta-analysis
Lyness, S. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00057-x · Cited by 240 · cited 1×
“Neuropathologic studies suggest that cell loss in the dorsal raphe (major site of cortical serotonin) in patients with AD is three times greater than in controls and comparable to losses in nucleus basalis and locus coeruleus, providing strong evidence that serotonergic loss is widespread in AD [22].”
ResultMcHugh, G. S., Butcher, I., Steyerberg, E. W., Marmarou, A., Lu, J., Lingsma, H. F., Weir, J., Maas, A. I. R., & Murray, G. D. (2010) · Clinical Trials · doi:10.1177/1740774509356580 · Cited by 108 · cited 1×
“This method has an adequate type I error proportion under the null hypothesis and provides substantial gains in efficiency relative to a binary analysis [17].”
MethodCitalopram for agitation in Alzheimer's disease: Design and methods
Drye, L. T., Ismail, Z., Porsteinsson, A. P., Rosenberg, P. B., Weintraub, D., Marano, C., Pelton, G., Frangakis, C., Rabins, P. V., Munro, C. A., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.01.007 · Cited by 52 · cited 1×
“The PSI was developed for the Clinical Antipsychotic Trials of Intervention Effectiveness Study [11], then modified and used successfully in the Depression in Alzheimer’s Disease Study–2 and in CitAD [12].”
MethodSelf-citationChange in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial
Rosenberg, P. B., Drye, L. T., Porsteinsson, A. P., Pollock, B. G., Devanand, D. P., Frangakis, C., Ismail, Z., Marano, C., Meinert, C. L., Mintzer, J. E., et al. (2015) · International Psychogeriatrics · doi:10.1017/s1041610215001106 · Cited by 28 · cited 1×
“Twenty six percent of patients in the placebo arm of CitAD had a positive response on PSI largely within three weeks [38].”
BackgroundSelf-citation
Cited by
Alzheimer’s disease drug development pipeline: 2020
Cummings, J., Lee, G., Ritter, A., Sabbagh, M., & Zhong, K. (2020) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12050 · Cited by 557
Pathogenesis, diagnostics, and therapeutics for Alzheimer's disease: Breaking the memory barrier
Kamatham, P. T., Shukla, R., Khatri, D. K., & Vora, L. K. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102481 · Cited by 371
Psychosis in Alzheimer disease—mechanisms, genetics and therapeutic opportunities
Ismail, Z., Creese, B., Aarsland, D., Kales, H. C., Lyketsos, C. G., Sweet, R. A., & Ballard, C. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-021-00597-3 · Cited by 189
Self-citationA 2023 update on the advancements in the treatment of agitation in Alzheimer’s disease
Lee, D., Clark, E. D., Antonsdottir, I. M., & Porsteinsson, A. P. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2195539 · Cited by 28
“Following CitAD, the S-CitAD study evaluates the safety and efficacy of escitalopram in a phase 3, multicenter, randomized, sequential-phase trial design funded by the NIA [71].”
BackgroundMethodSelf-citationSagar, R., Azoidis, I., Zivko, C., Xydia, A., Oh, E. S., Rosenberg, P. B., Lyketsos, C. G., Mahairaki, V., & Avramopoulos, D. (2023) · Cells · doi:10.3390/cells12151990 · Cited by 8
Self-citation
Metadata
- Authors
- Ehrhardt, S., Porsteinsson, A. P., Munro, C. A., Rosenberg, P. B., Pollock, B. G., Devanand, D. P., Mintzer, J., Rajji, T. K., Ismail, Z., Schneider, L. S., Baksh, S. N., Drye, L. T., Avramopoulos, D., Shade, D. M., Lyketsos, C. G., & S‐CitAD Research Group
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2019-10-03
- Volume
- 15
- Issue
- 11
- Pages
- 1427-1436
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2978577535
- Cited by
- 48
- References
- 13
- FWCI
- 3.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.